Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.39 |
| ▸ | HSP90AB1 | P08238 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | CPT2 | P23786 | 2/20 | 0.39 |
| ▸ | CPT1A | P50416 | 2/20 | 0.39 |
| ▸ | CPT1B | Q92523 | 1/20 | 0.39 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.38 |
| ▸ | TRPC3 | Q13507 | 1/20 | 0.38 |
| ▸ | TRPC6 | Q9Y210 | 1/20 | 0.38 |
| ▸ | BAZ2A | Q9UIF9 | 1/20 | 0.38 |
| ▸ | NAA50 | Q9GZZ1 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL166240 | 1.00 | TRPV1 (0.42) | TRPV1POLBHSP90AA1HSP90AB1SMN1; SMN2 | |
| SCHEMBL6466955 | 0.93 | BAZ2A (0.41) | TRPV1POLBHSP90AA1HSP90AB1SMN1; SMN2 | |
| SCHEMBL3511063 | 0.92 | TSHR (0.39) | TRPV1POLBHSP90AA1HSP90AB1SMN1; SMN2 | |
| SCHEMBL475795 | 0.92 | TSHR (0.39) | TRPV1POLBHSP90AA1HSP90AB1SMN1; SMN2 | |
| SCHEMBL6464489 | 0.92 | POLB (0.39) | TRPV1POLBHSP90AA1HSP90AB1SMN1; SMN2 | |
| SCHEMBL10290636 | 0.91 | BAZ2A (0.42) | TRPV1POLBHSP90AA1HSP90AB1SMN1; SMN2 | |
| SCHEMBL3513513 | 0.90 | POLB (0.38) | TRPV1POLBHSP90AA1HSP90AB1SMN1; SMN2 | |
| SCHEMBL475663 | 0.90 | POLB (0.38) | TRPV1POLBHSP90AA1HSP90AB1SMN1; SMN2 | |
| SCHEMBL2317005 | 0.89 | TSHR (0.38) | TRPV1POLBHSP90AA1HSP90AB1SMN1; SMN2 | |
| SCHEMBL3514481 | 0.89 | TSHR (0.38) | TRPV1POLBHSP90AA1HSP90AB1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2611441-A1 | BACE INHIBITORS FOR USE IN THE TREATMENT OF DIABETES | F.HOFFMANN-LA ROCHE AG (CH) | 2013-07-10 | — | — | EP | disclosed |
| WO-2012028563-A1 | BACE INHIBITORS FOR USE IN THE TREATMENT OF DIABETES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-03-08 | — | — | WO | disclosed |
| US-20120053200-A1 | BACE 2 INHIBITORS | HOFFMANN-LA ROCHE INC. | 2012-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053200-A1 | BACE 2 INHIBITORS | BACE2, BACE1, PSEN2 | TRPV1 2871/4885POLB 1391/4885HSP90AA1 3048/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.